Trial Profile
Do healthy males aged 18 years and older show an effect of Bremelanotide on social cognition and behaviour?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Bremelanotide (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 31 Mar 2021 Status changed from recruiting to completed.
- 31 Mar 2021 Inclusion criteria is updated to increase the minimum age limit from 16 to 18 years.
- 31 Mar 2021 Planned number of patients changed from 30 to 61.